Edarbi

Atrial Fibrillation, Albuminuria, Type 2 Diabetes + 2 more

Treatment

2 FDA approvals

20 Active Studies for Edarbi

What is Edarbi

Azilsartan medoxomil

The Generic name of this drug

Treatment Summary

Azilsartan medoxomil is a type of drug commonly used to treat high blood pressure. This drug is usually taken as a pill and is available under the brand name Edarbi. It works by blocking a hormone in the body that causes blood vessels to tighten and narrow, which can raise blood pressure. Azilsartan medoxomil can be taken alone or along with other medications to help lower blood pressure and reduce the risk of cardiovascular events such as heart attack and stroke. It may also be used off-label to treat patients with a history of myocardial infarction or heart failure.

Edarbi

is the brand name

image of different drug pills on a surface

Edarbi Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Edarbi

Azilsartan medoxomil

2011

10

Approved as Treatment by the FDA

Azilsartan medoxomil, otherwise known as Edarbi, is approved by the FDA for 2 uses including Hypertensive disease and inadequate response to monotherapy .

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

inadequate response to monotherapy

Used to treat inadequate response to monotherapy in combination with Chlorthalidone

Effectiveness

How Edarbi Affects Patients

Azilsartan medoxomil is a drug that helps lower blood pressure by blocking the angiotensin II receptor. This decreases the amount of pressure on the blood vessels, leading to a lower blood pressure. The effects of this drug are seen within one hour of taking the drug, and can last up to 24 hours. Taking azilsartan medoxomil does not affect potassium or sodium levels, and it does not have any effect on the production of angiotensin II or bradykinin. There is no need to adjust the dosage based on sex, race, or other factors.

How Edarbi works in the body

Azilsartan medoxomil helps regulate blood pressure by blocking the effects of a hormone called angiotensin II. Angiotensin II narrows blood vessels and increases the production of aldosterone, a hormone that helps the body retain water. Azilsartan medoxomil binds to AT1 receptors, blocking the effects of angiotensin II and reducing blood pressure. It is more effective than other similar drugs because it binds to AT1 receptors more strongly and stays attached for a longer period of time.

When to interrupt dosage

The advised dosage of Edarbi is reliant upon the specified condition, such as Hypertensive disorder, Atrial Fibrillation and Albuminuria. The dosage will be contingent on the method of delivery featured in the table hereafter.

Condition

Dosage

Administration

Atrial Fibrillation

40.0 mg, , 80.0 mg, 20.0 mg

Oral, Tablet, , Tablet - Oral

Hypertensive disease

40.0 mg, , 80.0 mg, 20.0 mg

Oral, Tablet, , Tablet - Oral

Albuminuria

40.0 mg, , 80.0 mg, 20.0 mg

Oral, Tablet, , Tablet - Oral

Type 2 Diabetes

40.0 mg, , 80.0 mg, 20.0 mg

Oral, Tablet, , Tablet - Oral

inadequate response to monotherapy

40.0 mg, , 80.0 mg, 20.0 mg

Oral, Tablet, , Tablet - Oral

Warnings

Edarbi Contraindications

Condition

Risk Level

Notes

Type 2 Diabetes

Do Not Combine

Anuria

Do Not Combine

There are 20 known major drug interactions with Edarbi.

Common Edarbi Drug Interactions

Drug Name

Risk Level

Description

Amifostine

Major

Azilsartan medoxomil may increase the hypotensive activities of Amifostine.

Lithium carbonate

Major

The serum concentration of Lithium carbonate can be increased when it is combined with Azilsartan medoxomil.

Lithium citrate

Major

The serum concentration of Lithium citrate can be increased when it is combined with Azilsartan medoxomil.

Lithium hydroxide

Major

The serum concentration of Lithium hydroxide can be increased when it is combined with Azilsartan medoxomil.

Sacubitril

Major

The risk or severity of angioedema can be increased when Azilsartan medoxomil is combined with Sacubitril.

Edarbi Toxicity & Overdose Risk

The maximum safe dose of azilsartan has not been determined yet. People have been able to tolerate doses of up to 320 mg per day, however. In the event of an overdose, supportive measures should be taken as azilsartan cannot be removed from the blood through dialysis. Azilsartan is also teratogenic, meaning it can cause birth defects in pregnant women, especially during the second and third trimesters.

image of a doctor in a lab doing drug, clinical research

Edarbi Novel Uses: Which Conditions Have a Clinical Trial Featuring Edarbi?

265 active trials are currently being conducted to investigate the potential of Edarbi to treat Atrial Fibrillation, inadequate response to monotherapy and Albuminuria.

Condition

Clinical Trials

Trial Phases

Type 2 Diabetes

89 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Albuminuria

1 Actively Recruiting

Phase 2

Atrial Fibrillation

86 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1

inadequate response to monotherapy

0 Actively Recruiting

Hypertensive disease

30 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Edarbi Reviews: What are patients saying about Edarbi?

5

Patient Review

12/22/2016

Edarbi for High Blood Pressure

I switched to Edarbi from another blood pressure medication because of the side effects I was experiencing. It's been working really well for me at a lower dose, and my blood pressure has been great.

5

Patient Review

6/9/2020

Edarbi for High Blood Pressure

Out of the four different ARB drugs I was prescribed, Edarbi 40mgs is the only one that worked for me. My blood pressure has been constantly at 125/83, which is better than 140/96. Additionally, I experienced no negative side effects.

5

Patient Review

11/7/2016

Edarbi for High Blood Pressure

I was first given 40mg of this medication, and while my blood pressure did drop slightly, I am now on 80mg and feeling much better than before.

4.7

Patient Review

12/11/2017

Edarbi for High Blood Pressure

It lowered my blood pressure without any side effects for 3 years now.

4.3

Patient Review

2/13/2019

Edarbi for High Blood Pressure

I started taking Edarbi after being diagnosed with high blood pressure. My first dose was 40mg once a day, but after just two days my blood pressure crashed to 90/60. I stopped taking the pill and monitored my BP for seven days, which stayed below 140/90. Edarbi is a very strong medication, so I have had to quarter the pills to get 10mg per dose. At this lower dosage, I am able to maintain a normal BP of 120/80 both day and night.

4.3

Patient Review

5/27/2021

Edarbi for High Blood Pressure

I've been taking Edarbyclor for three months now. While it's helped with the muscle spasms, the gastrointestinal symptoms are really bad. I get nauseous, have diarrhea, and experience a lot of bloating. I'm hoping that it's just something in my diet that can be easily controlled, but we'll see.

3.7

Patient Review

12/16/2018

Edarbi for High Blood Pressure

I've been on Edarbi for two weeks now. It does lower my blood pressure, but I experience dizziness if I stand up too quickly or bend over.

3

Patient Review

4/17/2019

Edarbi for High Blood Pressure

I'm not a fan of this drug because it gives me heart flutters. I'm anxious about the abnormal rhythms it's been causing, so I've scheduled an appointment with my doctor. Fingers crossed that they'll put me back on something else.

3

Patient Review

7/15/2022

Edarbi for High Blood Pressure

The side effects were pretty harsh: fatigue, stomach bloating, wheezing, depression and respiratory congestion.

3

Patient Review

9/30/2016

Edarbi for High Blood Pressure

This treatment does well in controlling my blood pressure, but I've been having a lot of back pain and sometimes an odd taste in my mouth.

2.7

Patient Review

6/1/2016

Edarbi for High Blood Pressure

Didn't help my blood pressure as much as I needed, and caused other problems like fatigue and leg cramps. The eczema was the worst part, though.

2.3

Patient Review

5/3/2016

Edarbi for High Blood Pressure

Nausea, awful taste in mouth, and feeling like a zombie are just some of the side effects I experienced. The pill did work, but it's not worth how I felt afterwards.

2.3

Patient Review

2/10/2016

Edarbi for High Blood Pressure

I started taking Edarbi a few days ago because I'd gained weight from my previous medication. However, after only five days on Edarbi I've already gained three pounds and have been in severe pain on my right side and lower back. The pain has been preventing me from sleeping, so I'm going to call the doctor today and stop taking the drug.

1

Patient Review

10/24/2018

Edarbi for High Blood Pressure

The leg pain was unbearable, and I constantly felt nauseous. We increased the dosage from 40mg to 80mg, but it still didn't lower my blood pressure effectively. In fact, I gained eight pounds in six weeks while taking this medication.

1

Patient Review

2/12/2017

Edarbi for High Blood Pressure

I was on this treatment for a little over two weeks. It lowered my blood pressure to the point of dehydration and caused muscle cramps. I overall felt very dizzy and lightheaded while taking it and did not feel good at all. I decided to switch to a different drug.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about edarbi

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Edarbi and losartan?

"Edarbi (azilsartan) lowers blood pressure and is more expensive than other medicines that work similarly. Cozaar (Losartan) lowers your blood pressure and protects kidney function like an ACE inhibitor, but with fewer side effects which lowers your risk for stroke and heart attack."

Answered by AI

What medication is similar to Edarbi?

"Edarbi is also used to treat kidney problems caused by type 2 diabetes.

The drugs Avapro and Edarbi are both angiotensin II receptor blockers (ARBs), which are used to treat hypertension (high blood pressure). In some cases, Avapro is prescribed alongside other blood pressure medications. Additionally, Avapro can also be used to ameliorate kidney problems that are caused by type 2 diabetes (non-insulin-dependent). Similarly, Edarbi is also effective in treating kidney problems resulting from type 2 diabetes."

Answered by AI

What's the side effects of Edarbi?

"The side effects of the medication include nausea, diarrhea, fatigue, cough, dizziness on standing, weakness or lack of energy, and feeling tired."

Answered by AI

Is Edarbi a good blood pressure medicine?

"You can take control of your high blood pressure by using EDARBI, an angiotensin II receptor blocker. EDARBI relaxes your blood vessels, which lowers your blood pressure."

Answered by AI

Clinical Trials for Edarbi

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Have you considered Edarbi clinical trials?

We made a collection of clinical trials featuring Edarbi, we think they might fit your search criteria.
Go to Trials
Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Northwestern University in Chicago, United States.

Exercise Program for Atrial Fibrillation and Heart Failure

60 - 99
All Sexes
Chicago, IL

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL). Limitations being able to participate in activities of daily living is a primary complaint for AF-HFpEF patients, yet effective strategies to address this issue remain limited. While exercise interventions targeting aerobic training (AT) are recommended for patients with AF and HFpEF, unique challenges exist in this patient population who tend to be older. Specifically, many older patients with AF and HFpEF have muscle weakness, sarcopenia and frailty, that can make aerobic-focused exercise difficult and less tolerable. This study proposes that starting with progressive resistance training (PRT) before aerobic exercise may overcome these issues by improving muscle strength, making AT more manageable, and leading to better health outcomes. The goal of this study is to assess whether a sequential exercise program, named 'PREACTIVE' improves how people feel, decrease the amount of symptoms, and their ability to participate in exercise and activities. This study will specifically test a sequenced exercise approach of resistance training followed by aerobic exercise to improve symptoms, and quality of life in AF-HFpEF.

Waitlist Available
Has No Placebo

Northwestern University

Deepika Laddu, PhD

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Meal Macronutrients for Blood Fat Levels

18 - 120
All Sexes
Bethesda, MD

Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome. Objective: To learn more about how different types of foods affect fat levels in the blood. Eligibility: People aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed. Design: Participants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal. Participants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after. Participants will have other tests during their stays: * A resting metabolic test captures the air they exhale and measures how much energy they use at rest. * A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have. * A Fibroscan is a special type of ultrasound of the liver. * A body surface scan uses lasers to measure the total area of the body. * A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body. Participants may opt to have a third visit. At this visit, the breakfast will be high in protein.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Rebecca J Brown, M.D.

Have you considered Edarbi clinical trials?

We made a collection of clinical trials featuring Edarbi, we think they might fit your search criteria.
Go to Trials
Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Edarbi clinical trials?

We made a collection of clinical trials featuring Edarbi, we think they might fit your search criteria.
Go to Trials